Algeta starts dosimetry study with Alpharadin

Algeta, a Norwegian cancer therapeutics company, has begun, as planned, enrolment for a clinical dosimetry study as part of its continuing program to provide further supporting clinical documentation for its lead anticancer product, Alpharadin, a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 which may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

The trial is an open-label, dosimetry, biodistribution, excretion and pharmacokinetic evaluation in patients with hormone refractory prostate cancer and skeletal metastases. It will enroll up to 10 patients and will be conducted at a major cancer research center in the UK.

Algeta is preparing to enter Alpharadin into Phase III trials in 2008 following positive Phase II clinical data, reported recently and published in Lancet Oncology, which demonstrate its clear potential as a new treatment for this indication.